Literature DB >> 20331452

Impaired lymphocyte mitochondrial antioxidant defences in variegate porphyria are accompanied by more inducible reactive oxygen species production and DNA damage.

Miguel D Ferrer1, Antoni Sureda, Pedro Tauler, Clara Palacín, Josep A Tur, Antoni Pons.   

Abstract

This study aimed to analyse lymphocyte reactive oxygen species (ROS) production and detoxification mechanisms and the appearance of oxidative damage in variegate porphyria (VP) patients. Twelve women affected by VP and 12 pair-matched healthy control women participated in the study. VP women presented impaired expression of the mitochondrial proteins protoporphyrinogen oxidase, uncoupling protein-3, Bcl-2 and sirtuin 3. Lymphocytes from VP women presented higher H(2)O(2) production than controls after stimulation with phorbol myristate acetate. The inhibition of H(2)O(2) production after in vitro lymphocyte treatment with myxothiazol pointed towards complex III of the mitochondrial respiratory chain as the main contributor of the higher ROS production in porphyric subjects. No differences were observed between VP and control subjects in the levels of DNA damage, assessed by the comet assay method in un-treated lymphocytes. However, DNA damage, expressed both as a percentage of DNA in tail and as the tail moment, was greater in VP women than controls after lymphocyte treatment with H(2)O(2). In conclusion, lymphocytes from VP women showed impaired expression of mitochondrial antioxidant defences but no significant signs of oxidative stress were evidenced in basal, non-stressing conditions; however, lymphocytes of VP women were more susceptible to producing mitochondrial ROS and to suffering oxidative damage when submitted to stressful situations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20331452     DOI: 10.1111/j.1365-2141.2010.08149.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

1.  Phytoestrogens enhance antioxidant enzymes after swimming exercise and modulate sex hormone plasma levels in female swimmers.

Authors:  Antonia Mestre-Alfaro; Miguel D Ferrer; Antoni Sureda; Pedro Tauler; Elisa Martínez; Maria M Bibiloni; Vicente Micol; Josep A Tur; Antoni Pons
Journal:  Eur J Appl Physiol       Date:  2011-02-18       Impact factor: 3.078

2.  Clinical, biochemical, and genetic characterization of acute hepatic porphyrias in a cohort of Argentine patients.

Authors:  María Del Carmen Martinez; Gabriela Nora Cerbino; Bárbara Xoana Granata; Alcira Batlle; Victoria Estela Parera; María Victoria Rossetti
Journal:  Mol Genet Genomic Med       Date:  2021-03-25       Impact factor: 2.183

3.  Effects of docosahexaenoic supplementation and in vitro vitamin C on the oxidative and inflammatory neutrophil response to activation.

Authors:  Xavier Capó; Miquel Martorell; Antoni Sureda; Josep Antoni Tur; Antoni Pons
Journal:  Oxid Med Cell Longev       Date:  2015-04-19       Impact factor: 6.543

4.  Haem Biosynthesis and Antioxidant Enzymes in Circulating Cells of Acute Intermittent Porphyria Patients.

Authors:  Miguel D Ferrer; Antonia Mestre-Alfaro; Magdalena Martínez-Tomé; Lucrecia Carrera-Quintanar; Xavier Capó; Antonia M Jiménez-Monreal; Luis García-Diz; Enrique Roche; María A Murcia; Josep A Tur; Antoni Pons
Journal:  PLoS One       Date:  2016-10-27       Impact factor: 3.240

5.  Two weeks of hydrogen inhalation can significantly reverse adaptive and innate immune system senescence patients with advanced non-small cell lung cancer: a self-controlled study.

Authors:  Ji-Bing Chen; Xiao-Feng Kong; Wei Qian; Feng Mu; Tian-Yu Lu; You-Yong Lu; Ke-Cheng Xu
Journal:  Med Gas Res       Date:  2020 Oct-Dec

6.  Anti-Cancer Effects of Auranofin in Human Lung Cancer Cells by Increasing Intracellular ROS Levels and Depleting GSH Levels.

Authors:  Xia Ying Cui; Sun Hyang Park; Woo Hyun Park
Journal:  Molecules       Date:  2022-08-15       Impact factor: 4.927

7.  Hydrogen therapy can be used to control tumor progression and alleviate the adverse events of medications in patients with advanced non-small cell lung cancer.

Authors:  Ji-Bing Chen; Xiao-Feng Kong; Feng Mu; Tian-Yu Lu; You-Yong Lu; Ke-Cheng Xu
Journal:  Med Gas Res       Date:  2020 Apr-Jun
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.